Effects of a SGLT2 inhibitor on glucose metabolism and body composition in patients with type 2 diabetes

Trial Profile

Effects of a SGLT2 inhibitor on glucose metabolism and body composition in patients with type 2 diabetes

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Oct 2017

At a glance

  • Drugs Tofogliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Oct 2017 New trial record
    • 15 Sep 2017 Results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
    • 15 Sep 2017 Status changed from not yet recruiting to completed, based on the results presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top